Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2452-2459

  Cheng, Hui Chuan ^a   Liu, Yu Peng ^a   Shan, Yan Shen ^a,b   Huang, Chi Ying ^c   Lin, Forn Chia ^a   Lin, Li Ching ^d   Lee, Ling ^d   Tsai, Chen Hsun ^a   Hsiao, Michael ^e   Lu, Pei Jung ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; MESSENGER RNA; OSTEOPONTIN; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; STOMACH CANCER; STOMACH EPITHELIUM; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 3 SUBUNIT; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84887009130     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt218     Document Type: Article

References (37)

1. Eheman,C. et al.(2012) Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer, 118, 2338-2366.
2. Jemal,A. et a l. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
3. Meza-Junco,J. et al. (2012) Metastatic gastric cancer-focus on targeted therapies. Biologics, 6, 137-146.
4. Fukamachi,H. et al. (2004) Growth regulation of gastric epithelial cells by Runx3. Oncogene, 23, 4330-4335.
5. Levanon,D. et al . (2002) The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J., 21, 3454-3463.
6. Woolf,E. et al . (2007) Runx3 regulates dendritic epidermal T cell development. Dev. Biol., 303, 703-714.
7. Sheng,Z. et al (2009) Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R. EMBO J., 28, 866-876.
8. Lin,F.C. et al. (2012) RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene, 31, 4302-4316.
9. Giambra,V. et al. (2012) NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-Θ and reactive oxygen species. Nat. Med., 18, 1693-1698.
10. Voon,D.C. et al. (2012) Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells, 30, 2088-2099.
11. Peng,Z. et al. (2006) RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin. Cancer Res., 12, 6386-6394.
12. Hsu,P.I. et al. (2009) Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann. Surg. Oncol., 16, 1686-1694.
13. Tanaka,S. et al. (2012) Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int. J. Cancer, 131, 2537-2546.
14. Denhardt,D.T. et al. (1995) Osteopontin-induced modifications of cellular functions. Ann. N. Y. Acad. Sci., 760, 127-142.
15. Anborgh,P.H. et al . (2010) Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J. Cell. Mol. Med., 14, 2037-2044.
16. Fong,Y.C. et al. (2009) Osteopontin increases lung cancer cells migration via activation of the alphavbeta3integrin/FAK/Akt and NF-kappaBdependent pathway. Lung Cancer, 64, 263-270.
17. Wang,Y. et al. (2011) Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur. J. Cell Biol., 90, 642-648.
18. Song,G. et al. (2009) Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J. Cell. Mol. Med., 13, 1706-1718.
19. Singhal,H. et al. (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res., 3, 605-611.
20. Schneider,S. et al . (2004) Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin. Cancer Res., 10, 1588-1596.
21. Ue,T. et al. (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer, 79, 127-132.
22. Sodek,J. et a l. (2000) Osteopontin. Crit. Rev. Oral Biol. Med., 11, 279-303.
23. Chatterjee,M. (2001) Vitamin D and genomic stability. Mutat. Res., 475, 69-87.
24. El-Tanani,M.K. et a l (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev., 17, 463-474.
25. Xing,X. et al. (2011) Involvement of MAPK and PI3K signaling pathway in sterigmatocystin-induced G2 phase arrest in human gastric epithelium cells. Mol. Nutr. Food Res., 55, 749-760.
26. Dai,N. et al. (2007) Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology, 72, 89-96.
27. Hijiya,N. et a . (1994) Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J., 303(Pt 1), 255-262.
28. Wai,P.Y. et al. (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev., 27, 103-118.
29. Prince,M. et al. (2001) Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. J. Cell. Biochem., 80, 424-440.
30. Hess,J. et al. (2001) AP-1 and Cbfa/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2/AP-1 composite element. J. Biol. Chem., 276, 20029-20038.
31. Inman,C.K. et al. (2003) The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J. Biol. Chem., 278, 48684-48689.
32. Sakakura,C. et al. (2005) Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer. Int. J. Cancer, 113, 221-228.
33. Gu,Y.X. et al. (2013) The roles of PI3K/Akt signaling pathway in regulating MC3T3-E1 preosteoblast proliferation and differentiation on SLA and SLActive titanium surfaces. J. Biomed. Mater. Res. A, 101, 748-754.
34. Chen,H.T. et al. (2012) Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway. PLoS One, 7, e38378.
35. Kumar,S. et al. (2012) Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3kinase/Akt signaling pathway. Curr. Mol. Med., 12, 952-966.
36. Fainaru,O. et al. (2005) Accelerated chemokine receptor 7-mediated dendritic cell migration in Runx3 knockout mice and the spontaneous development of asthma-like disease. Proc. Natl Acad. Sci. USA, 102, 10598-10603.
37. Mei,P.J. et al . (2011) RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J. Cancer Res. Clin. Oncol., 137, 1823-1830.